Edit
OncoGenex Pharmaceuticals
http://www.oncogenex.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 18.11.2016
Probably Closed
Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
Total raised: $50M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.03.2012 | - | $50M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.11.2016 | Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash | UK antibiotic developer Motif Bio (AIM: MTFB) may have sorted out its financial woes, for now. The biotech made a deal to float its US IPO, conditional on a European placement to raise $25 million. And the company says it... |
| 16.08.2016 | Hopes fading, OncoGenex acknowledges a PhIII flop for cancer drug | Any dwindling hopes that investors still had in OncoGenex $OGXI largely evaporated Tuesday morning when the Seattle-based biotech reported that its late-stage effort for custirsen failed a Phase III study for castration res... |
| 17.09.2013 | BDC Venture Capital Is Giving $135 Million to Healthcare Tech | The Business Development Bank of Canada (BDC) is making one big bet on healthcare technologies. The BDC’s Venture Capital arm announced today that it has allocated $135 million in new capital to direct venture investments in innovative heal... |
| 02.08.2012 | OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Pity Scott Cormack. As the CEO of an aspiring prostate cancer drug developer, he’s got to answer to the masters at the FDA and the cancer physicians who want unequivocal, long... |
| 16.03.2012 | OncoGenex Snags $50M for Prostate Cancer Drug Plan | Share Share on Facebook Share on Twitter LinkedIn Email Reprints OncoGenex Pharmaceuticals decided it needed to spend more money on the final stage of clinical trials for its prostate cancer drug, so today it went out and raised a lot more ... |
| 08.11.2010 | OncoGenex Hires Burris | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Bothell, WA-based OncoGenex Pharmaceuticals (NASDAQ: OGXI) said today it has hired Michelle Burris as its executive vice president of operations and chief financial officer. B... |
| 19.10.2010 | OncoGenex Raises $50M | Share Share on Facebook Share on Twitter LinkedIn Email Reprints OncoGenex Pharmaceuticals (NASDAQ: OGXI), the Bothell, WA-based developer of cancer drugs, said today it has raised $50 million through a new securities offering. The company ... |
| 16.12.2008 | Prostate Cancer Drug Vaults OncoGenex Onto Investor Radar Screens | Share Share on Facebook Share on Twitter LinkedIn Email Reprints The best-performing stock on the Nasdaq last week was a little biotech company from the Pacific Northwest that few people had heard of before. The company was OncoGenex Pharma... |